UNSPSC 51183616: Insulin peglispro

This classification denotes a peptide hormone C8H16N2O4(C2H4O)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Y83I5F10I, chemically known as poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-methoxy-, 28b-ester with 28b-(n6-carboxy-l-lysine)-29b-l-prolineinsulin (human), but more generally known as insulin peglispro, which bears US NIH Compound Identifier 71301236. Most nations, for tariff and trade purposes, schedule insulin peglispro under HS 29371200 and SITC 54154.

SMILES: As of Q4 2014, INSULIN PEGLISPRO remains US FDA's Preferred Term for this commodity.

UNSPSC 51183616 Insulin peglispro is a Commodity code covering a specific pharmaceutical product — a long-acting basal insulin analog — that state and local governments procure primarily through Medicaid programs, corrections departments, and public health agencies for patient treatment and disease management. State and local buyers source this product through group purchasing organizations, state pharmaceutical benefit managers, and direct vendor agreements to supply insulin-dependent patients across multiple care settings including hospitals, clinics, correctional facilities, and community health centers. The code reflects a narrow, high-specificity product line rather than a broad service family; procurement activity centers on formulary inclusion, pricing negotiations, and supply chain management rather than competitive service delivery or construction work.

The source provides no recent state or local contract opportunities tagged to this code, so current market activity cannot be characterized by issuing-body type, geographic spread, or representative solicitation. Insulin peglispro procurement typically occurs through standing Medicaid contracts, master supply agreements managed by state pharmaceutical offices, and blanket purchase orders rather than individual posted RFPs or RFQs, which may explain the absence of recent visible opportunities in public notice channels. A business development professional evaluating this code should monitor state Medicaid agency contract registers, pharmaceutical benefit manager RFQs, and group purchasing organization vendor add-on notices rather than relying on open-market solicitation postings.